Brain tumors can be primary (originating in the brain) or secondary (metastatic spread from other cancers). Common primary brain tumors include glioblastoma, astrocytoma, oligodendroglioma, meningioma, and medulloblastoma. Secondary brain tumors are metastases from another site; mostly commonly lung cancer, breast cancer, melanoma, colon and kidney cancer. We offer a full range of advanced radiation therapy technologies, from stereotactic radiosurgery to fractionated whole-brain radiation therapy with hippocampal sparing.
Glioblastoma is the most common and most aggressive primary malignant brain tumor. The current standard of treatment includes maximal safe surgical resection followed by concurrent chemotherapy and radiotherapy with temozolomide, followed by adjuvant temozolomide therapy.
The radiation therapy course is typically 6 weeks, however shorter courses called hypofractionation radiation therapy can be utilized depending on a patient’s clinical status. The treatment is typically delivered utilizing intensity modulated radiation therapy, or IMRT, which helps to minimize the dose to surrounding normal healthy tissue. We work closely with our medical or neuro oncologists who prescribe the oral chemotherapy given concurrently with radiation therapy.
Once a patient has completed their radiation therapy course, they may be a candidate for Optune which our ROC physicians can help coordinate. Optune is a wearable cancer-treatment device that uses alternating electric fields to help make it harder for cancer cells to reproduce.
Stereotactic radiosurgery or SRS is the ideal treatment for brain metastases and small benign tumors such as meningiomas or vestibular schwannomas. In a single session (or 3-5 fractions for larger lesions), we deliver a high ablative dose with submillimeter precision using either a Gamma Knife or a linear accelerator equipped with micro-multi-leaf collimators.
For patients with multiple brain metastases, whole‑brain radiotherapy may be necessary. However, conventional WBRT carries a significant risk of cognitive decline—up to 50% of patients develop memory loss and executive dysfunction within 4‑6 months.
At ROC, we use hippocampal‑avoidance WBRT (HA‑WBRT). By intentionally excluding the hippocampus (the brain’s memory center) from the high‑dose region, we reduce the risk of radiation‑induced dementia. We combine HA‑WBRT with a memantine prescription to further protect cognitive function.
Call us at 847-698-0600 ext. 112 to schedule a consultation. Our team works closely with neurosurgeons to help give you the best possible outcome.
Schedule your visit and manage payments with ease.
Our specialists are available for consultation. Contact us to discuss your diagnosis and treatment with confidence.